As one of the first medical device categories entering national centralized procurement, coronary drug eluting stents provide an interesting case study on how healthcare systems attempt to balance:
✅ Clinical evidence
✅ Quality requirements
✅ Regulatory approvals
✅ Competition
✅ Patient access
The proposed approach reviews 45 Sirolimus-coated stents from 35 manufacturers and 19 Everolimus-coated stents from 9 manufacturers, using a structured grouping methodology rather than relying on price alone.
What I find most interesting is that the discussion is no longer just about purchasing products.
It is increasingly about evaluating evidence.
In this carousel, I’ve summarized:
📌 The key grouping principles
📌 The proposed Sirolimus and Everolimus subgroup structures
📌 How clinical evidence is incorporated into procurement design
📌 Why competition remains a core requirement across subgroups
Swipe through the slides below 👇
💬 If you were designing a national stent tender, what should carry the greatest weight: clinical evidence, regulatory maturity, competition, or affordability?
Read full summarized document “Vietnam National Drug Eluting Stent Tender” here: https://lnkd.in/p/dFHBXvGC